First patent from a new patent family granted in China, strengthening the long‑term intellectual property protection for the Company’s lead product candidate Oslo, Norway, 19 March 2026: Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces […]
12 March 2026- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the appointment of Dr Adrian Kilcoyne to its Scientific Advisory Board. Dr Kilcoyne brings over 20 years of clinical expertise with strategic drug development leadership, focusing on innovative therapies that address unmet medical needs in oncology […]
Dr. Thomas L. F. Montgomery Andresen joins from T-Cypher Bio Follows breakthrough non-human primate data demonstrating deep B-cell depletion without cytokine release Commit is poised to nominate its first two clinical development candidates later in 2026 COPENHAGEN, Denmark — March 11, 2026 — Commit Biologics (“Commit”), a biotechnology company pioneering complement system activation and backed […]
9 of 10 patients at the highest dose remained free from peritoneal recurrence at 24 months at the recommended dose Oslo, Norway, 17 February 2026 – Oncoinvent, a biotech developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announced that it will present […]
Oslo, Norway, 16 February 2026: Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, is pleased to invite investors, analysts, and stakeholders to a live webcast event at 9:30 AM CET on Thursday, 26 February 2026. Second half […]
